Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/63170
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3392]
Metadata
Show full item record
BRAIN DAMAGE SERUM BIOMARKERS INDUCED BY COVID‑19 IN PATIENTS FROM NORTHEAST BRAZIL
Author
Affilliation
Federal University of Pernambuco. Research Center in Immunomodulation and New Therapeutic Approaches Suely Galdino. Laboratory of Immunomodulation and New Therapeutic Approaches. Recife, PE, Brazil.
Federal University of Pernambuco. Research Center in Immunomodulation and New Therapeutic Approaches Suely Galdino. Laboratory of Immunomodulation and New Therapeutic Approaches. Recife, PE, Brazil / Federal University of Pernambuco. Biochemistry Department. Recife, PE, Brazil.
Federal University of Pernambuco. Research Center in Immunomodulation and New Therapeutic Approaches Suely Galdino. Laboratory of Immunomodulation and New Therapeutic Approaches. Recife, PE, Brazil.
Federal University of Pernambuco. Research Center in Immunomodulation and New Therapeutic Approaches Suely Galdino. Laboratory of Immunomodulation and New Therapeutic Approaches. Recife, PE, Brazil.
Federal University of Pernambuco. Research Center in Immunomodulation and New Therapeutic Approaches Suely Galdino. Laboratory of Immunomodulation and New Therapeutic Approaches. Recife, PE, Brazil.
Federal University of Pernambuco. Research Center in Immunomodulation and New Therapeutic Approaches Suely Galdino. Laboratory of Immunomodulation and New Therapeutic Approaches. Recife, PE, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Federal University of Pernambuco. Research Center in Immunomodulation and New Therapeutic Approaches Suely Galdino. Laboratory of Immunomodulation and New Therapeutic Approaches. Recife, PE, Brazil / Federal University of Pernambuco. Physiology and Pharmacology Department. Recife, PE, Brazil.
Federal University of Pernambuco. Research Center in Immunomodulation and New Therapeutic Approaches Suely Galdino. Laboratory of Immunomodulation and New Therapeutic Approaches. Recife, PE, Brazil / Federal University of Pernambuco. Biochemistry Department. Recife, PE, Brazil.
Federal University of Pernambuco. Research Center in Immunomodulation and New Therapeutic Approaches Suely Galdino. Laboratory of Immunomodulation and New Therapeutic Approaches. Recife, PE, Brazil / Federal University of Pernambuco. Biochemistry Department. Recife, PE, Brazil.
Federal University of Pernambuco. Research Center in Immunomodulation and New Therapeutic Approaches Suely Galdino. Laboratory of Immunomodulation and New Therapeutic Approaches. Recife, PE, Brazil / Federal University of Pernambuco. Biochemistry Department. Recife, PE, Brazil.
Federal University of Pernambuco. Research Center in Immunomodulation and New Therapeutic Approaches Suely Galdino. Laboratory of Immunomodulation and New Therapeutic Approaches. Recife, PE, Brazil.
Federal University of Pernambuco. Research Center in Immunomodulation and New Therapeutic Approaches Suely Galdino. Laboratory of Immunomodulation and New Therapeutic Approaches. Recife, PE, Brazil.
Federal University of Pernambuco. Research Center in Immunomodulation and New Therapeutic Approaches Suely Galdino. Laboratory of Immunomodulation and New Therapeutic Approaches. Recife, PE, Brazil.
Federal University of Pernambuco. Research Center in Immunomodulation and New Therapeutic Approaches Suely Galdino. Laboratory of Immunomodulation and New Therapeutic Approaches. Recife, PE, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Federal University of Pernambuco. Research Center in Immunomodulation and New Therapeutic Approaches Suely Galdino. Laboratory of Immunomodulation and New Therapeutic Approaches. Recife, PE, Brazil / Federal University of Pernambuco. Physiology and Pharmacology Department. Recife, PE, Brazil.
Federal University of Pernambuco. Research Center in Immunomodulation and New Therapeutic Approaches Suely Galdino. Laboratory of Immunomodulation and New Therapeutic Approaches. Recife, PE, Brazil / Federal University of Pernambuco. Biochemistry Department. Recife, PE, Brazil.
Federal University of Pernambuco. Research Center in Immunomodulation and New Therapeutic Approaches Suely Galdino. Laboratory of Immunomodulation and New Therapeutic Approaches. Recife, PE, Brazil / Federal University of Pernambuco. Biochemistry Department. Recife, PE, Brazil.
Abstract
Neurological symptoms have been often reported in COVID-19 disease. In the present study, we evaluated brain damage associated with the increase of serum levels of neurological biomarkers S100B and neuron-specific enolase (NSE) induced by SARS-CoV-2 infection, in a population from Northeastern Brazil. Thirty-six healthy control (G1) individuals and 141 patients with confirmed COVID-19 were enrolled in this study. Positive-COVID-19 patients were divided into two groups according to the severity of illness by the National Institute of Health (NIH) criteria, 76 patients with mild symptoms for COVID-19 and (G2) and 65 with acute respiratory conditions requiring supplemental oxygenation via intensive care unit (ICU) admission (G3). A follow-up study was conducted with 23 patients from G2 14 (D14) and 21 (D21) days after the onset of symptoms. Serum levels of NSE and S100B were measured using the enzyme-linked immunoassay method (ELISA). Results revealed a significant positive association between G3 patients and S100B serum expression (p = 0.0403). The serum levels of NSE were also significantly enhanced in the G3 group compared to the control (p < 0.0001) and G2 group (p < 0.0001). In addition, clinical features such as symptoms and oxygenation status were not correlated with NSE or S100B serum expression. The follow-up study demonstrated a decrease over time (21 days) in NSE serum expression (p < 0.0001). These results suggest that brain damage is followed by acute virus exposure, with no long-term effects. Future work examining COVID-19 recovery will shed light on chronic neurological damage of SARS-CoV-2 infection.
Share